[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
June 1995

Photodynamic Therapy of Experimental Choroidal Neovascularization Using Lipoprotein-Delivered Benzoporphyrin

Author Affiliations

From the Laser Research Laboratory, Retina Service, Massachusetts Eye and Ear Infirmary (Drs Miller, Walsh, Kramer, Haimovici, and Gragoudas), and the Department of Dermatology, Wellman Laboratories of Photomedicine, Massachusetts General Hospital (Drs Hasan and Flotte and Mr Michaud), Harvard Medical School, Boston. The Massachusetts Eye and Ear Infirmary has a proprietary interest in this technology under a reasearch agreement with Coherent Inc, Palo Alto, Calif, and as part of a patent application. Drs Miller and Gragoudas are participants in this agreement and application under the established guidelines of Harvard Medical School.

Arch Ophthalmol. 1995;113(6):810-818. doi:10.1001/archopht.1995.01100060136048

Objective:  To investigate photodynamic therapy of experimental choroidal neovascularization using benzoporphyrin derivative monoacid (Verteporfin).

Methods:  Photodynamic therapy using benzoporphyrin derivative monoacid was investigated in cynomolgus monkeys. Following intravenous injection of benzoporphyrin derivative monoacid (1 to 2 mg/kg) complexed with low-density lipoprotein, the eyes were irradiated with 692-nm light at a fluence of 50 to 150 J/cm2 and irradiance of 150 to 600 mW/cm2. Choroidal neovascularization was documented before photodynamic therapy and closure was demonstrated by fundus photography, fluorescein angiography, and light and electron microscopic examination.

Results:  Following photodynamic therapy, vessels within choroidal neovascularization were occluded, and there was damage to the choroidal neovascularization endothelium and the subjacent choriocapillaris. Damage to the retinal pigment epithelium and photoreceptors was also observed.

Conclusion:  Photodynamic therapy with lipoprotein-delivered benzoporphyrin derivative monoacid was effective in this animal model of choroidal neovascularization and may be a promising, potentially selective, therapy for choroidal neovascularization.